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Abstract
 
Stimulation of Flt3 receptor tyrosine kinase through its cognate ligand expands early hemato-
poietic progenitor and dendritic cells (DCs) in humans and mice. The exact developmental
stages at which hematopoietic progenitors express Flt3, are responsive to its ligand, and subse-
quently develop to DCs, are not known. Here we show that common lymphoid and common
myeloid progenitors, as well as steady state DCs in thymus, spleen, and epidermis, express Flt3.
The receptor is down-regulated once definitive B cell, T cell, and megakaryocyte/erythrocyte
commitment occurs, and Flt3 is not detectable on other steady state hematopoietic cell popula-
tions. Upon in vivo Flt3 ligand (Flt3L) administration, Flt3
 
  
 
progenitor cells and their progeny
DCs are expanded, whereas Flt3
 
  
 
downstream progenitors are not, or are only slightly increased.
Transplantation of common lymphoid and common myeloid progenitors and subsequent Flt3L
injection increases progeny DCs of both precursor populations. These findings provide a defin-
itive map of Flt3 expression in the hematopoietic hierarchy and directly demonstrate that Flt3L
can drive DC development along both the lymphoid and myeloid developmental pathways
from Flt3
 
  
 
progenitors to Flt3
 
  
 
DCs.
Key words: Flt3/Flt3L • dendritic cells • development • hematopoietic progenitors
 
Introduction
 
Flt3 (also termed Flk-2 [1] and STK-1 [2]), a receptor tyro-
sine kinase with homology to c-Kit (the receptor for steel
factor [SLF]
 
*
 
/stem cell factor) and c-fms (the receptor for
M-CSF), is highly expressed in hematopoietic progenitor
cells (for review see 3). Important information about its
function in hematopoiesis has been gained through mice
with targeted gene disruption of Flt3 (4) or Flt3 ligand
(Flt3L; 5), through in vivo Flt3L injection (6–8) and
through overexpression of Flt3L (9, 10) or introduction of
constitutively active flt3 mutations (11) in hematopoietic
cells. Flt3
 
 
 
/
 
  
 
mice show normal peripheral blood counts,
however, pro-B cell numbers are diminished and bone
marrow progenitors of these mice display a reduced ability
to competitively reconstitute lethally conditioned recipi-
ents, most pronounced in the T and myeloid lineages (4).
Flt3L
 
 
 
/
 
  
 
mice show no significant changes in red blood
cells and platelets but 27–45% decreased numbers of com-
plete nucleated cells in peripheral blood, bone marrow,
spleen, and lymph nodes, most marked in relative lym-
phocyte numbers (5). In addition, the total numbers of
CFU-GM and B cell precursors are reduced (5). Flt3L
 
 
 
/
 
 
 
mice also show about fivefold lower numbers of NK cells
and 4–14-fold reduced, but functional DCs in lymphoid
organs (5). Injection of human Flt3L that displays a high
homology and is cross-reactive to mouse Flt3L is reported
to increase numbers of lymphocytes, granulocytes, and
monocytes, and massively mobilize immature, myeloid col-
ony-forming and long-term (6 mo) reconstituting cells into
peripheral blood (6). Also, it dramatically increases NK
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Abbreviations used in this paper:
 
 CLP, common lymphoid progenitor;
CMP, common myeloid progenitor; Flt3L, Flt3 ligand; GMP, granulo-
cyte/macrophage progenitor; HSC, hematopoietic stem cell; IPC, inter-
feron 
 
 
 
–producing cell; MEP, megakaryocyte/erythrocyte progenitor;
SLF, steel factor.T
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cells (12) and DCs in bone marrow and lymphoid organs
(4–27-fold), with up to 30% of spleen cells expressing
CD11c and MHC class II (8, 13). Mice with Flt3L overex-
pression or constitutive active Flt3 signaling develop my-
eloproliferative disease and are prone to develop leukemias
with both lymphoid and myeloid marker expression (9–
11). Finally, Flt3L as a single cytokine is able to induce all
major DC populations in vitro from whole bone marrow
cells (14, 15). Based on these data, Flt3 signaling has its
most pronounced effect on the expansion of early hemato-
poietic progenitor cells and on the generation of mature,
steady state NK cells and DCs.
We have recently isolated clonal common lymphoid and
myeloid progenitors in mouse bone marrow (16, 17) and
we and others demonstrated that both lymphoid and my-
eloid progenitors give rise to both CD8
 
 
 
  
 
and CD8
 
 
 
 
 
DCs in vivo (18–20). Also, we and others have shown that
short-term but not long-term hematopoietic stem cells
(HSCs) express Flt3 (21, 22). Given the relevance of Flt3/
Flt3L in early hematopoiesis and DC generation, here we
wanted to directly test (a) Flt3 receptor expression on de-
fined successive lymphoid and myeloid progenitors and on
mature, steady state hematopoietic cell populations, (b) in
vivo progenitor and mature hematopoietic cell expansion
in response to Flt3L, and (c) if Flt3L acts on the generation
of DCs along both the lymphoid and myeloid develop-
mental pathway.
 
Materials and Methods
 
Mice.
 
C57BL/Ka-Thy1.1 mice, homozygous for either
CD45.1 or CD45.2, and F1 C57BL/Ka-Thy1.1 (CD45.1 
 
 
 
CD45.2) mice were used as previously described (18, 19). All
mice were maintained in Stanford University’s Research Animal
Facility in accordance with Stanford guidelines.
 
Antibodies and Flow Cytometry.
 
The following antibodies
were used: M1/70 (anti–Mac-1/CD11b), 8C5 (anti–Gr-1), 6B2
(anti-B220), KT-31 (anti-CD3), GK1.5 (anti-CD4), 53-6.7
(anti-CD8
 
 
 
), anti-TER119, A7R34 (anti–IL-7R
 
 
 
/CD127),
2B8 (anti–c-Kit/CD117), 3C11 (anti–c-Kit/CD117), E13-161-7
(anti–Sca-1), 19XE5 (anti–Thy-1.1), A20.1.7 (anti-CD45.1),
AL1-4A2 (anti-CD45.2), 6C3 (anti–BP-1; own laboratory hy-
bridoma cell lines), and goat anti–rat IgG (PE or Cy5-PE conju-
gated; Caltag). Antibodies purchased from BD Biosciences:
2.4G2 (anti-Fc
 
 
 
RII/III), RAM34 (anti-CD34), NK1.1, S7 (anti-
CD43), 7D4 (anti–IL-2R
 
 
 
/CD25), 1D3 (anti-CD19), AF6-
120.1 (anti-IA
 
b
 
), HL3 (anti-CD11c), and rat IgG
 
2a 
 
as isotype con-
trol. Antibodies purchased from eBioscience: 30-F1 (anti-HSA/
CD24) and A2F10.1 (anti-Flt3/CD135). For visualization of
biotinylated antibodies, streptavidin-conjugated PE, Cy5-PE,
Cy7-PE, and Texas Red (Invitrogen) were used.
HSCs, lymphoid progenitors, myeloid progenitors, DC pre-
cursor–containing populations, and DCs were sorted as reported
elsewhere (16–19, 21, 23–25). Mature cells were sorted from
spleen or blood cells as follows: B cells: CD19
 
  
 
B220
 
 
 
; T cells:
CD3
 
  
 
TCR
 
 
 
  
 
NK1.1
 
 
 
; NK cells: NK1.1
 
  
 
CD3
 
 
 
; NKT cells:
NK1.1
 
  
 
CD3
 
 
 
; granulocytes: Gr-1
 
hi 
 
Mac-1
 
  
 
CD11c
 
 
 
; mono-
cytes/macrophages: Gr-1
 
 
 
/int 
 
Mac-1
 
  
 
CD11c
 
  
 
B220
 
 
 
. Langer-
hans cells were isolated and sorted as previously described (26).
For all experiments, dead cells were excluded by propidium io-
dide staining and appropriate isotype-matched, irrelevant control
monoclonal antibodies were used to determine the level of back-
ground staining.
Cells were sorted and analyzed using a modified dual laser
FACS Vantage™ (Becton Dickinson) and a dual laser MoFlo
 
®
 
cytometer (DakoCytomation), both equipped with a 488-nm ar-
gon laser and a 599-nm dye laser. All transplanted progenitors as
well as all cells for PCR analysis were purified by sorting and then
resorting, and were 
 
 
 
99% pure for the indicated surface marker
phenotype.
 
RT-PCR Analysis.
 
RNA was extracted from double sorted
populations, reverse transcribed to cDNA, and analyzed for the
presence of flt3 sequences as previously described (flt3 sense: 5
 
 
 
ACC ATG GAT TCG GGC TCA CCT 3
 
 
 
; flt3 antisense: 5
 
 
 
CTG GGC GTC ATC ATT TTC TGC 3
 
 
 
, 445-bp PCR prod-
uct; reference 27). 
 
  
 
actin was amplified as a control. PCR ampli-
fication consisted of an initial denaturation step at 94
 
 
 
C for 2 min,
followed by 30–38 cycles at 94
 
 
 
C for 30 s, annealing at 65
 
 
 
C for
30 s, and extension at 72
 
 
 
C for 60 s in each cycle. PCR products
were electrophoresed on an ethidium bromide–stained 1.5% aga-
rose gel. For each PCR, RNA equivalents from 125 cells (pro-
genitors) or 500 cells (splenocytes) were used. PCR amplification
was repeated at least twice for at least three separately prepared
cDNA samples for each experiment.
 
In Vitro DC Differentiation Assay.
 
Common lymphoid pro-
genitors (CLPs) and common myeloid progenitors (CMPs) were
differentiated in vitro into DCs as previously described (19). In
brief, CLPs were cultured over 5 d in Iscove’s modified Dul-
becco medium (Invitrogen) supplemented with 10% FCS, 10
 
 
 
4 
 
M
2-mercaptoethanol, sodium pyruvate, antibiotics, and 10 ng/
ml recombinant mouse IL-1
 
 
 
, 20 ng/ml IL-3, 10 ng/ml IL-4,
10 ng/ml IL-7, 10 ng/ml TNF
 
 
 
, 10 ng/ml SLF, and 10 ng/ml
Flt3L. CMPs were cultured over 8 d in 20 ng/ml IL-3, 10 ng/
ml IL-4, 10 ng/ml TNF
 
 
 
, 10 ng/ml SLF, 10 ng/ml Flt3L, and
10 ng/ml GM-CSF. Peripheral spleen monocytes were cultured
over 5 d in the media described above supplemented with 10
ng/ml IL-4, 10 ng/ml GM-CSF, and where indicated, 10 ng/
ml Flt3L. In additional experiments sorted Flt3
 
  
 
and Flt3
 
  
 
CLPs
or CMPs were cultured on a confluent layer of irradiated (25
Gy) murine AC6 stromal cells as previously described (28) with
the addition of 10 ng/ml IL-7, 10 ng/ml SLF, and 10 ng/ml
Flt3L for CLPs or 10 ng/ml SLF and 10 ng/ml Flt3L for CMPs
to provide cells with an optimized support for in vitro develop-
ment.
 
In Vivo Reconstitution Assays and Flt3L Injection.
 
For in vivo
reconstitution assays, purified progenitors or whole bone marrow
cells were injected i.v. into 8–12-wk-old sublethally (4.75 Gy) or
lethally irradiated (9.5 Gy) congenic mice, which differed only at
the CD45 allele. Donor-derived DCs were evaluated at different
time points after transplantation as previously described (18, 19).
Flt3L (10 
 
 
 
g in 100 
 
 
 
l PBS; provided by Immunex) or control
PBS was injected daily s.c. as previously described (8) over the
time indicated in the results section.
 
Results
 
Flt3 Is Expressed on CLPs and CMPs and Is Subsequently
Down-regulated in B Cell, T Cell, and Megakaryocyte/Erythro-
cyte Commitment.
 
Flt3 receptor expression was tested by
nonquantitative RT-PCR and for quantitative assessment,
by FACS
 
®
 
. As reported before (21, 22), the Lin
 
  
 
c-Kit
 
 
 
Thy-1.1
 
  
 
Sca-1
 
  
 
population contains Flt3-expressing cells,T
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which are short-term HSCs (Fig. 1, A and E). Flt3 is highly
up-regulated in a major fraction of CLP (60–70%) and is
consecutively reduced in pro-B and pro-T cells. Although
on both pro-B (A) and pro-T1 cells, Flt3 is detectable as
surface protein by FACS
 
®
 
, only RT-PCR reveals Flt3 ex-
pression in pro-B (BC) cells and neither method shows it
in pro-T2 cells (Fig. 1, A and E, and not depicted). During
myeloid commitment, Flt3 is highly expressed on more
than half of CMPs (50–65%) and is reduced to lower levels
on granulocyte/macrophage progenitors (GMPs), whereas
it is not detectable on cells committed to the megakary-
ocyte-erythrocyte lineage (megakaryocyte/erythrocyte
progenitors [MEPs]; Fig. 1, A and E). Therefore, Flt3 is
transiently up-regulated during both lymphoid and my-
eloid commitment, but consecutively down-regulated in
definitive B cell, T cell, and megakaryocyte/erythrocyte
lineage development.
 
Flt3 Is Expressed on Steady State DCs, but Not on Other
Mature Steady State Hematopoietic Cells.
 
To test whether
Flt3 is expressed on mature cells of hematopoietic origin
under steady state conditions, we evaluated all major nucle-
ated cell lineages isolated from spleen. Only CD11c
 
  
 
MHC
class II
 
  
 
DCs but not B cells, T cells, NK cells, NKT cells,
granulocytes, and monocytes/macrophages expressed flt3
mRNA or Flt3 surface protein (Fig. 1 B and not depicted).
Further analysis of DC subpopulations showed that Flt3 is
expressed in CD8
 
 
 
  
 
CD11b
 
  
 
and CD8
 
 
 
  
 
CD11b
 
  
 
DCs in
spleen and thymus as well as in Langerhans cells of the epi-
dermis and, at slightly lower levels, on CD11c
 
lo 
 
B220
 
  
 
Gr-1
 
 
 
interferon 
 
 
 
–producing cells (IPCs; Fig. 1, C and F, and
Figure 1. Flt3 expression on defined hematopoietic
progenitor cells, steady state DCs, and other mature
hematopoietic cells. Expression of Flt3 was examined
by nonquantitative RT-PCR on (A) hematopoietic
progenitor populations from bone marrow and thy-
mus, (B) on mature hematopoietic cells from spleen
(BC, B cells; TC, T cells; NK, NK cells; NKT, NKT
cells; DC, dendritic cells; Gr, granulocytes; M ,
monocytes/macrophages), and (C) on steady state DC
populations as indicated from bone marrow (bm),
blood, spleen (spl), thymus (thy), and Langerhans cells
(LC) from the epidermis. (D) In vitro–derived DCs
(CD11c   I-Ab ) from either splenic monocytes or
common myeloid and lymphoid progenitors were
sorted, and Flt3 expression was analyzed by RT-PCR.
(E) FACS® analysis of Flt3 surface expression is shown
on the left panel. thin line, HSCs; bold line, CLPs;
dashed line, whole bone marrow for comparison. In
the middle panel: thin line, CMPs; bold line, GMPs;
dashed line, MEPs. On the right panel: thin line, pro-B
cells; bold line, pro-T1 cells from thymus; dashed line,
whole thymus. (F) Flt3 expression on CD11c  I-Ab 
cells (thin line) and CD11c  I-Ab  cells (bold line)
from bone marrow (left) and spleen (middle). Right
panel shows FACS® analysis of IPCs in the spleen.
Dashed lines in F always show staining with the accord-
ing isotype control antibody.T
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not depicted). Therefore, with the exception of follicular
DCs that were not analyzed, all major steady state DC pop-
ulations in primary and secondary lymphoid tissues and in
the epidermis express Flt3 whereas other mature cell popu-
lations do not.
Because early lymphoid and myeloid progenitors as
well as steady state DCs expressed Flt3, we were inter-
ested to test whether Flt3 is continuously expressed during
DC development. CD11c
 
  
 
MHC class II
 
  
 
cells in blood
were recently described as immediate DC-committed
progenitors (25). As the residence time of tested nucleated
cells (T cells and B cells, granulocytes, monocytes, LT-
HSCs, ST-HSCs, and multipotent progenitors/MPP) can
be measured in minutes (29), it can also be assumed that
blood CD11c
 
  
 
MHC class II
 
  
 
cells are brief transients
from bone marrow to tissues where both they should be
contained in cell populations that display a similar pheno-
type. Although bone marrow CD11c
 
  
 
MHC class II
 
  
 
and
CD11c
 
  
 
MHC class II
 
  
 
cells expressed high levels of Flt3,
we were not able to detect Flt3 in blood and spleen
CD11c
 
  
 
MHC class II
 
  
 
cells and only low levels in blood
CD11c
 
  
 
MHC class II
 
  
 
DCs (Fig. 1, C and F). Therefore,
if CD11c
 
  
 
MHC class II
 
  
 
cells in blood and spleen are in-
deed the major immediate DC progenitor populations of
lymphoid organ DCs, Flt3 would be transiently down-
regulated in development and consecutively up-regulated
on DCs again.
 
Flt3 Is Expressed on Lymphoid and Myeloid Progenitor–
derived, but Not on Monocyte-derived, DCs In Vitro.
 
To test
whether DCs derived from different precursors express
Flt3, CLPs, CMPs, and spleen monocytes/macrophages
were cultured, and differentiated CD11c
 
  
 
MHC class II
 
 
 
cells were sorted for RT-PCR analysis. DCs derived from
both CLPs and CMPs expressed Flt3, whereas no Flt3 sig-
nal could be detected on DCs derived from Flt3
 
  
 
mono-
cytes (Fig. 1 D). Therefore, although in vitro–derived
DCs from early Flt3  progenitors are Flt3 , Flt3 expres-
sion seems not to be an essential prerequisite for DC de-
velopment and is not expressed on monocyte-derived DCs
in vitro.
Flt3 , but Not Flt3 , Lymphoid- and Myeloid-committed
Progenitors Generate DCs. As shown above, both CLPs
and CMPs are heterogeneous in Flt3 expression. There-
fore, we wanted to investigate if Flt3  and/or Flt3  CLPs
and CMPs, respectively, would generate DCs (Fig. 2). To
do so we isolated subpopulations of CLP and CMP accord-
ing to their expression of Flt3 and tested their developmen-
tal potential. 2,000 highly purified cells of each population
were cultured per well in the presence of AC6 stroma cells
and cytokines that provided an optimized environment for
DC development in vitro. After 6 d cultures were analyzed
by FACS® for the generation of lymphoid and/or myeloid
cells as well as DCs. The data in Fig. 2 show that CLPs,
whether they express Flt3 or not, give rise to B cells identi-
Figure 2. Only Flt3  CLPs and CMPs generate DCs. Flt3  and Flt3  subpopulations of CLPs and CMPs were sorted and 2,000 cells each were cul-
tured in vitro on AC6 stroma cells in presence of IL-7/SLF/Flt3L for CLPs or SLF/Flt3L for CMPs. After 6 d these cultures were analyzed by FACS®
and the percentages of the DC populations are given. Plots showing CMP-derived cells are gated on SSClow/intermediate cells to exclude macrophages with
characteristically high autofluorescence. Data shown are representative for three independent experiments.T
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fied by their expression of CD19. But only the Flt3  sub-
population also give rise to CD11c  DCs that are mainly
positive for MHC II. In contrast, the majority of CMP-
derived cells were CD11bhi macrophages ( 80% in aver-
age) characterized by their high autofluorescence proper-
ties. The FACS® plots showing CMP progeny in Fig. 2 are
therefore gated on SSClow/intermediate cells to exclude cells
with a high autofluorescence. No CD19  B cells were de-
tected. But comparable to the result with CLPs, only the
Flt3   subpopulation of CMPs was able to generate
CD11c  MHC II  DCs. Therefore, Flt3  CLPs have lym-
phoid and DC potential and Flt3  CMPs have myeloid and
DC potential. Thus, Flt3 expression on CLPs or CMPs
does not define a Flt3  common DC progenitor. Rather,
DC developmental potential segregates with both the lym-
phoid and myeloid lineage.
Flt3L Expands Flt3-expressing Lymphoid- and Myeloid-com-
mitted Progenitor Cells but No or Little of Their Immediate
Downstream Flt3  Progeny In Vivo. To directly test the ef-
fect of Flt3 stimulation on successive early hematopoietic
progenitors, mice were injected with human Flt3L and
relative and absolute numbers of progenitors were evalu-
ated by FACS® after 5 and 10 d of injection, respectively
(Fig. 3 and Table I). All lymphoid and myeloid Flt3  pro-
genitors expanded and, with the exception of pro-B (Fig.
3 A) cells, showed higher expansion levels after 5 d com-
pared with 10 d. Remarkably, GMPs showed the highest,
near 10-fold, overall expansion. Thus, although Flt3-
expressing progenitors were expanded through cognate
ligand stimulation, immediate downstream Flt3  progeny
populations were not or only slightly, possibly due to the
lack of concurrent up-regulation of additional cytokines
necessary for further differentiation as IL-7 for lymphoid
or thrombopoietin/erythropoietin for megakaryocyte/
erythrocyte development.
Flt3L Expands DCs, Natural Interferon-producing Cells, Im-
mature Myeloid Cells, Granulocytes, and Monocytes, but Not T
Cells and B Cells, in Spleen. Next, we wanted to test how
numbers of mature cell types would be affected under
Flt3L injection and how this is correlated with expansion
and Flt3 expression of their respective progenitor cells.
Therefore, we analyzed spleen cells after 5 and 10 d of
Flt3L injection (Table II). CD11c  IAb  DCs and CD11clo
Gr-1  B220  IPCs (24, 30, 31) continuously expanded in
relative and absolute numbers to reach on average a 21-fold
and 35-fold expansion after 10 d of injection, respectively.
Gr-1hi  CD11b   CD11c   immature myeloid cells and
neutrophils expanded about equally (25.5-fold). Gr-1 /lo
CD11b   CD11c   B220   immature myeloid cells and
monocytes expanded 4.8-fold. In contrast, B cell and T cell
numbers were nearly unchanged (Table II). Therefore, be-
yond the expected expansion of CD11c  IAb  DCs (8),
these data confirm that IPC numbers can be dramatically
increased through Flt3L (30). Also, although CLPs, pro-B
Figure 3. Flt3L expands hematopoietic progenitors. FACS® analysis of hematopoietic progenitor populations in the bone marrow after 5 and 10 d of
s.c. Flt3L injections. Mice injected for 5 and 10 d (not depicted) with PBS were used as a control. (A) HSCs (electronically gated on Lin /lo Thy1.1lo
cells). (B) CLPs (gated on Lin /lo Thy1.1  IL-7R  ). (C) CMPs (CD34  CD16/32lo), GMPs (CD34  CD16/32hi), and MEPs (CD34  CD16/32lo;
gated on Lin /lo Sca-1  c-Kit  cells). (D) Pro-B cells (gated on IgM  NK1.1  B220  CD43  cells): pro B (A) are CD24 /lo 6C3  and pro-B (BC) are
CD24 . Numbers delineate relative percentages of the according population in total bone marrow.T
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(A) cells, and pro-T1 cells are expanded by Flt3L, this did
not lead to an increase in mature B cell and T cell numbers.
In contrast, Flt3L-induced expansion of GMPs lead to a
massive increase in immature myeloid cells and neutrophils,
and a moderate increase in monocytes.
Flt3L Supports DC Development along Both a Lymphoid
and Myeloid Developmental Pathway In Vivo. Finally, we
wanted to test if Flt3L supports DC development from
both CLPs and CMPs in vivo. We first evaluated whether
Flt3L would expand DC numbers in irradiated animals
transplanted with hematopoietic cells. Lethally (9.5 Gy) or
sublethally (4.75 Gy) irradiated mice were transplanted
with 2   105 congenic whole bone marrow cells. Flt3L was
injected over 10 d, starting on day 2 after transplantation,
and mice were evaluated 1 d after the last Flt3L injection.
In Flt3L-injected mice, donor-derived spleen CD11c 
IAb  DC numbers were on average 3.7-fold (9.5 Gy) and
5.4-fold (4.75 Gy) increased (two experiments each involv-
ing two mice per group; not depicted). Host spleen DCs
were hardly detectable above background in lethally irradi-
ated animals and were almost unchanged compared with
controls in sublethally irradiated mice (1.2-fold expansion;
not depicted). Therefore, Flt3L injection leads to an in-
crease in DC numbers in irradiated and whole bone
marrow–transplanted animals early after transplantation,
although this increase is minor compared with DC expan-
Table I. Flt3L Expands Lymphoid and Myeloid Progenitors In Vivo
5 Days 10 Days Fold expansion
Control Flt3L s.c. Control Flt3L s.c. 5 Days 10 Days
percent total no.  103 percent total no.  103 percent total no.  103 percent total no.  103
HSCa 0.03 17.5 0.14 96.6 0.03 16.2 0.09 65.3 5.5 4
CLPa 0.03 12.5 0.05 34.5 0.02 10.8 0.04 29 2.8 2.7
CMPa 0.22 110 0.71 490 0.22 119 0.48 348 4.4 2.9
GMPa 0.5 250 3.5 2,415 0.4 216 1.9 1,378 9.7 6.4
MEPa 0.12 60 0.1 69 0.08 43.2 0.065 47.1 1.2 1.1
pB(A)a 0.4 200 0.5 345 0.45 243 1.8 1,305 1.7 5.4
pB(BC)a 1.5 750 1.3 897 1.5 810 0.4 290 1.2 0.36
pT1b 0.02 30 0.08 104 0.02 30 0.05 60 3.5 2
pT2b 0.07 105 0.15 195 0.06 90 0.05 60 1.9 0.7
Relative percentages and total cell count of hematopoietic progenitor populations in bone marrow of two hind alegs or bthymus after 5 and 10 d of
Flt3L or PBS injection, respectively. Results represent means of three to four animals per group and are representative of three independent
experiments.
Table II. Expansion of Spleen Cells after Flt3L Injections
5 Days 10 Days Fold expansion
Control Flt3L s.c. Control Flt3L s.c. 5 Days 10 Days
percent total no.  103 percent total no.  103 percent total no.  103 percent total no.  103
B cells 61 67,100 54 72,900 55 67,000 26 68,900 1.1 1.0
T cells 35 38,500 36 48,600 36 44,000 21 55,600 1.3 1.3
Neutrophils 0.9 990 1.6 2,160 0.5 610 5.9 15,630 2.2 25.5
Monocytes 3.3 3,600 6.1 8,235 2 2,400 9.4 11,470 2.3 4.8
DCs 0.6 660 2.7 3,645 0.6 730 12.6 15,370 5.5 21
IPCs 0.04 44 0.07 95 0.05 61 1.4 1,708 2.2 28
CLP-DCsa 0.1 106 0.35 424 3.9
CMP-DCsa 0.17 176 0.47 572 3.2
Changes in relative percentages and total cell number of mature hematopoietic populations in the spleen after 5 and 10 d of injections with Flt3L or
PBS (control group), respectively. Results represent means of three to four animals per group and are representative of three independent experiments. 
aPercentages and total numbers of CLP- and CMP-derived DCs in spleens of transplanted animals after 10 d of Flt3L or PBS treatment, respectively.
Results represent means of three experiments each involving two to four animals in the Flt3L injection and two mice in the control group.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
311 Karsunky et al.
sion in Flt3L-injected healthy animals, possibly due to
competing cytokine signals in irradiation-induced hemato-
poietic damage. Upon transplantation of 104 CLPs and 2  
104  CMPs into 4.75 Gy irradiated animals, CLP- and
CMP-derived CD11c  IAb  spleen DCs expanded on av-
erage 3.9-fold and 3.2-fold (Table II and Fig. 4). These
results directly demonstrate that Flt3L can drive DC devel-
opment and expansion from both Flt3-expressing early
lymphoid- and myeloid-committed progenitors in vivo.
Discussion
Immunophenotypic characterization and isolation of
highly enriched hematopoietic progenitor cell populations
at defined successive stages of development provides the
means to study sequential changes in gene expression pro-
files during commitment to a lineage and the differentia-
tion into a mature cell type. Here we mapped mRNA and
cell surface expression of Flt3 on uncommitted and consec-
utive lineage–committed early hematopoietic progenitors
and on mature steady state haematolymphoid cells, and we
tested their in vivo response to Flt3L.
In early hematopoiesis, our findings show that Flt3 is
transiently up-regulated from short-term HSCs (21, 22) in
a substantial fraction of CLPs (60–70%) and CMPs (50–
65%). Flt3 is maintained at low levels in early GMP-com-
mitted progenitor cells, and is down-regulated and lost
once definitive B cell (pro-B[BC]), T cell (pro-T2), and
megakaryocyte/erythrocyte (MEP) lineage commitment
occurs (Fig. 1). Flt3 , but no or little of Flt3 , progenitors
are expanded by in vivo Flt3 stimulation (Fig. 3 and Table
I). These findings explain the observations that in vivo ap-
plication of Flt3L massively increases and depletion of
Flt3L decreases mixed (CFU-GEMM), CFU-GM, as well
as B cell colony forming units, but no or little of CFUs or
mature cells of the erythroid or megakaryocytic lineage
(6), and are in agreement with previous reports evaluating
Flt3 expression on nonclonally defined hematopoietic pro-
genitor cell populations in mice and humans (1, 32–36).
The dramatic increase of GMPs and downstream immature
myeloid cells (Tables I and II) underlines the importance
Flt3L as a myelopoietic factor, and it shall be important to
determine whether this is independent of G-CSF and
GM-CSF action.
In contrast to other hematopoietic lineages, develop-
mental options for at least CD8   and CD8   DCs are
conserved beyond both early lymphoid and myeloid com-
mitment (17, 19, 20), and here we directly show that Flt3L
can drive DC development along both pathways (Fig. 4
and Table II). Because Flt3 is expressed on progenitors and
mature, steady state DCs, and all Flt3  cells are expanded
by Flt3L, an important question is whether Flt3 expression
and signaling is a prerequisite for DC development. Flt3-
expressing CLPs, pro-T1 cells, CMPs, and GMPs have in
vitro and in vivo DC developmental potential, whereas
Flt3  fractions of CLPs, CMPs, and Flt3  MEPs do not
(18–20). We were not able to detect Flt3 in pro-T2 cells.
However, on a population basis, pro-T2 cells are able to
develop into DCs (19, 37). Also, Flt3  monocytes generate
DCs in vitro (Fig. 1) and likely in vivo (38). Conversely,
pro-B (A) cells clearly express Flt3, but DC development
from pro-B cells is still under debate. It was claimed that
whole pro-B cells have DC potential (39), however, we
were not able to detect this (19), whereas in a more speci-
fied evaluation, minor DC potential resided only in a very
early pro-B (A1) fraction (with similarities to CLPs), but
not within more mature pro-B cells (40). Thus, most but
not all Flt3  progenitors can develop into DCs, but Flt3
expression seems not to be essential for all DC precursor
cells. Developmental outcome might be regulated by com-
peting signals, in the case of pro-B cells possibly by the up-
regulation of Pax 5 (41). It should be valuable to test
whether overexpression and stimulation of Flt3 can “res-
cue” progenitors to the DC lineage that normally have lost
DC developmental potential.
Another critical question is whether Flt3L-expanded
Flt3   progenitors are primed to develop into DCs or
whether they retain their original developmental capacities.
We did not detect differences in the in vivo and in vitro
lymphoid or myeloid read out, nor did we observe superior
DC read out from in vivo Flt3L-expanded CLPs, CMPs,
and GMPs (unpublished data). Therefore, Flt3 stimulation
and consecutive expansion of early, defined progenitor
populations seems not to change their biology, in agree-
ment with previous data on Flt3-expanded, nonpurified
progenitor cells (6, 7).
Figure 4. Flt3L expands CLP- and CMP-derived DCs in vivo. 104
CD45.1  CLPs and 2   104 CD45.2  CMPs were competitively trans-
planted into sublethally irradiated CD45.1/CD45.2 F1 mice. Flt3L or
control PBS was injected over 10 d, starting on day 2 after transplanta-
tion, and mice were evaluated 1 d after the last Flt3L injection. Lower left
contour plot shows CD11c-enriched splenic progeny of CLPs (1), host
cells (2), and CMPs (3). CD11c and MHC II expression of cells in gates
1, 2, and 3 are shown in contour plots A, B, and C, respectively. Average
expansions of CLP- and CMP-derived DCs are indicated. Plots show DC
read out of a Flt3L-injected animal and are representative of three experi-
ments involving two to four mice in the Flt3L-treated group and two an-
imals as controls each. For relative and total numbers of CLP- and CMP-
derived DCs see Table II.T
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In contrast to preceding data, where surface Flt3 was not
observed on DCs (8), we detected both mRNA and low
surface protein expression on all evaluated major steady
state DC populations, and on DCs generated in vitro from
CLPs and CMPs, but not from monocytes (Fig. 1, C and F,
and unpublished data). Flt3 on DCs might be functionally
important for DC biology, e.g., in the interaction with T
cells that express membrane-bound Flt3L (42), alterna-
tively, low Flt3 surface expression on steady state DCs
might be a remainder of development. Indeed, CD11c 
MHC class II  cells in bone marrow that might contain
immediate DC precursors express high levels of Flt3 (Fig. 1
F), however, blood cells that are reported to be DC re-
stricted (25) and spleen cells with the same phenotype are
Flt3 . Therefore, Flt3 is either consecutively up-regulated
on DCs again, or alternatively, the CD11c  MHC class II 
cell populations isolated from blood and spleen would not
present an exclusive fraction of DC progenitors.
Given the importance of in vivo Flt3/Flt3L (5, 8), but
not GM-CSFR/GM-CSF (8, 43), on DC numbers in
lymphoid organs, how do our findings integrate Flt3L ver-
sus other DC-promoting cytokines, such as GM-CSF in a
model of DC homeostasis? Likely, most of lymphoid tissue
DCs derive from Flt3  progenitors during steady state DC
turnover, whereas few derive from Flt3  monocytes. This
might change dramatically in inflammation, where GM-
CSF becomes an abundant cytokine and tissue monocytes/
macrophages likely mature to DCs that migrate to lymph
nodes (38).
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